Results 11 to 20 of about 16,215 (185)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +2 more sources

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab

International Medical Case Reports Journal, 2018
Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Athina Pallikari, Constantine D Georgakopoulos Department of Ophthalmology, University of Patras, Patras, Greece Purpose: To report the 12-month outcomes of a patient switching from intravitreal ...
Makri OE, Tsapardoni FN, Plotas P, Pallikari A, Georgakopoulos CD   +4 more
doaj   +1 more source

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj   +1 more source

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj   +1 more source

Early high-dose aflibercept 8 mg clinical outcomes in wet age-related macular degeneration patients resistant to aflibercept 2 mg or faricimab. [PDF]

Acta Ophthalmol
Acta Ophthalmologica, Volume 104, Issue 7, Page e885-e887, November 2026.
Sutinen P, Hecht I, Tuuminen R.
europepmc   +2 more sources

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês, João Coelho, Luísa Malheiro, Angelina Meireles, Sílvia Monteiro, João Figueira, Bernardete Pessoa, Inês Carneiro, Constança Coelho, João Nuno Melo Beirão   +20 more
core   +1 more source

Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration” [PDF]

CPT Pharmacometrics Syst Pharmacol
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
Bihorel S, Chiu J, Chittenden J, Eissing T, Turner K, Höchel J, He Z, Davis J, Harnisch L.   +8 more
europepmc   +2 more sources

Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration [PDF]

, 2020
Purpose:The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD).Design:Retrospective, nonrandomized, comparative study.Methods:This was a ...
Subramanyam, Anand, Pandey, Priti, Chhablani, Jay Kumar, Abhishek Heranjal, Apoorva Ayachit, Tiwari, Sarvesh, Jay Chhablani, Heranjal, Abhishek, Sarvesh Tiwari, Salti, Haytham I.S., Priti Pandey, Ahmad Mansour, Ayachit, Apoorva G., Mansour, Ahmad Mohammed Farid Mahmoud, Chattannavar, Goura, Goura Chattannavar, Mohamad A Mansour, Sumit Randhir Singh, Anand Subramanyam, Haitham Salti, Singh, Sumit Randhir, Mansour, Mohamad A.   +21 more
core   +1 more source

Influence of aflibercept on platelet activation profile

, 2018
Aflibercept appears to accumulate in systemic circulation following intravitreal injections in therapy of neovascular age-related macular degeneration. This gives raise to the question of whether aflibercept affects platelets and their function such as ...
Sopova, K, Ziemssen, F, Grimmel, C, Sobolewska, B, Gatsiou, A, Stellos, K, Biedermann, T, Schenke-Layland, K, Poeschel, S, Golenko, J   +9 more
core   +6 more sources